



YOUR VISION IS OUR VISION™

## Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

June 16, 2023

*Regulated Information*

**Leuven, BELGIUM, Boston, MA, US – June 16, 2023 – 7.00 PM CET** Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received a transparency notification as follows:

Oxurion received a transparency notification on June 13, 2023, from Atlas Special Opportunities LLC indicating that as of June 8, 2023, it held 66,108,807 shares of the then outstanding 1,142,744,404 shares, and therefore crossed above the threshold (5%) by virtue of the sale and acquisition of voting securities. See Annex 1.

### **About Oxurion**

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at [www.oxurion.com](http://www.oxurion.com).

### **Important information about forward-looking statements**

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

### **For further information please contact:**

<u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 <a href="mailto:tom.graney@oxurion.com">tom.graney@oxurion.com</a>	<u>US</u> <u>Conway Communications</u> Mary T. Conway <a href="mailto:mtconway@conwaycommsir.com">mtconway@conwaycommsir.com</a>
Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 <a href="mailto:michael.dillen@oxurion.com">michael.dillen@oxurion.com</a>	<u>ICR Westwicke</u> Christopher Brinzey Tel: +1 617 835 9304 <a href="mailto:Chris.Brinzey@westwicke.com">Chris.Brinzey@westwicke.com</a>

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

### **ANNEX 1**

1) Status of the notification

Final

2) Issuer

Name OXURION  
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights



4) Notification by

A person that notifies alone



5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577



6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)



Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

08/06/2023 (DD/MM/YYYY)


8) Threshold that is crossed (in %)

5

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

1,142,744,404


 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	19,092,777	66,108,807	0	5.79%	0.00%
<b>TOTAL</b>		<b>66,108,807</b>	<b>0</b>	<b>5.79%</b>	<b>0.00%</b>

 Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone".  
For groups, start with the ultimate controlling natural person or legal entity.  
The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
Holders of equivalent financial instruments						
<b>TOTAL</b>				<b>0</b>	<b>0.00%</b>	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	<b>CALCULATE</b>	66,108,807	5.79%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  0 voting rights as of  (DD/MM/YYYY)

13) Additional information

On 06/06/2023 Atlas Special Opportunities LLC received 67,234,424 shares, as a result of which its shareholding increased to 67,234,424 shares (= 6.17%) (denominator = 1,089,578,053 shares). On the same date (06/06/2023) Atlas Special Opportunities LLC sold 8,968,575 additional shares, as a result of which its shareholding decreased to 58,265,849 shares (= 5.35%) (denominator = 1,089,578,053 shares). On 07/06/2023 Atlas Special Opportunities LLC sold 16,975,713 shares, as a result of which its shareholding decreased to 41,290,136 shares (= 3.79%) (denominator = 1,089,578,053 shares).  
On 08/06/2023 Atlas Special Opportunities LLC received 53,166,351 shares, as a result of which its shareholding increased to 94,456,487 shares (= 8.27%) (denominator = 1,142,744,404 shares). On the same date (08/06/2023) Atlas Special Opportunities LLC sold 28,347,680 shares, as a result of which its shareholding decreased to 66,108,807 shares (= 5.79%) (denominator = 1,142,744,404 shares).

Done at  New York  
On  12/06/2023 (DD/MM/YYYY)  
Name & capacity  Patrick Vance, proxyholder  
Signature  Patrick Vance

Attachments

- [EN](#)
- [NL](#)